Literature DB >> 10918051

Transmembrane phosphoprotein Cbp positively regulates the activity of the carboxyl-terminal Src kinase, Csk.

S Takeuchi1, Y Takayama, A Ogawa, K Tamura, M Okada.   

Abstract

Csk (carboxyl-terminal Src kinase) is a cytoplasmic tyrosine kinase that phosphorylates a critical tyrosine residue in each of the Src family kinases (SFKs) to inhibit their activities. Recently, we identified a transmembrane protein, Cbp (Csk-binding protein), that, when phosphorylated, can recruit Csk to the membrane where the SFKs are located. The Cbp-mediated relocation of Csk to the membrane may play a role in turning off the signaling events initiated by SFKs. To further characterize the Csk-Cbp interaction, we have generated a reconstituted system using soluble, highly purified proteins. Csk and phosphorylated Cbp were co-purified as a large protein complex consisting of at least four Csk.Cbp units. The addition of the phosphorylated, but not nonphosphorylated, Cbp to an in vitro assay stimulated Csk activity toward Src. Csk was also activated by a phosphopeptide containing the tyrosine in Cbp that binds to Csk (Tyr-314). Kinetic analysis revealed that Cbp or the phosphopeptide induced up to a 6-fold reduction in the K(m) for Src, indicating that the Csk.Cbp complex has a greater affinity for Src than free Csk. These findings suggest that Cbp is involved in the regulation of SFKs not only by relocating Csk to the membrane but also by directly activating Csk.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10918051     DOI: 10.1074/jbc.C000326200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

Review 1.  Reciprocal regulation of lymphocyte activation by tyrosine kinases and phosphatases.

Authors:  Michelle L Hermiston; Zheng Xu; Ravindra Majeti; Arthur Weiss
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

Review 2.  Positive and negative regulation of T-cell activation through kinases and phosphatases.

Authors:  Tomas Mustelin; Kjetil Taskén
Journal:  Biochem J       Date:  2003-04-01       Impact factor: 3.857

Review 3.  Modulation of T cell immune functions by the prostaglandin E(2) - cAMP pathway in chronic inflammatory states.

Authors:  Kristoffer Watten Brudvik; Kjetil Taskén
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 4.  Positive and negative adaptors in T-cell signalling.

Authors:  Beverley Wilkinson; Hongyan Wang; Christopher E Rudd
Journal:  Immunology       Date:  2004-04       Impact factor: 7.397

5.  Expression and purification of human PAG, a transmembrane adapter protein using an insect cell expression system and its structure basis.

Authors:  Satoru Takeuchi
Journal:  Protein J       Date:  2006-06       Impact factor: 2.371

6.  Actin depolymerization transduces the strength of B-cell receptor stimulation.

Authors:  Shengli Hao; Avery August
Journal:  Mol Biol Cell       Date:  2005-02-23       Impact factor: 4.138

7.  Identification of N-terminal lobe motifs that determine the kinase activity of the catalytic domains and regulatory strategies of Src and Csk protein tyrosine kinases.

Authors:  Kezhen Huang; Yue-Hao Wang; Alex Brown; Gongqin Sun
Journal:  J Mol Biol       Date:  2009-03-06       Impact factor: 5.469

8.  Purification, crystallization, small-angle X-ray scattering and preliminary X-ray diffraction analysis of the SH2 domain of the Csk-homologous kinase.

Authors:  Natalie J Gunn; Michael A Gorman; Renwick C J Dobson; Michael W Parker; Terrence D Mulhern
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2011-02-23

9.  Laminin alters fyn regulatory mechanisms and promotes oligodendrocyte development.

Authors:  Jenne Relucio; Iva D Tzvetanova; Wei Ao; Sabine Lindquist; Holly Colognato
Journal:  J Neurosci       Date:  2009-09-23       Impact factor: 6.167

10.  The tyrosine kinase Csk dimerizes through Its SH3 domain.

Authors:  Nicholas M Levinson; Patrick R Visperas; John Kuriyan
Journal:  PLoS One       Date:  2009-11-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.